On 8/28/24, Neurocrine Biosciences Inc (NASDAQ: NBIX) stock suffered a major decline of -18.9%, closing at $123.76. Moreover, trading volume in this decline was exceptionally high at 556% of normal. Relative to the market the stock has been strong over the last nine months but has declined -17.3% during the last week.
Current PriceTarget Research Rating
NBIX is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Neurocrine Biosciences has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Neurocrine Biosciences has a neutral Appreciation Score of 43 and a slightly positive Power Rating of 67, with the Neutral Value Trend Rating the result.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment